Zhaoke Hefei was honored with the 2024 “New Force Enterprise” of Hefei High-tech Zone

Zhaoke Hefei was honored with the 2024 “New Force Enterprise” of Hefei High-tech Zone

Recently, the list of the 2024 “New Force Enterprises” of Hefei High-tech Zone was announced. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke- Hefei”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, stock code: 00950), was successfully recognized as “New Force Enterprise” for its outstanding performance in technological innovation, industrial influence, and new […]

The Group’s product Treprostinil Injection featured in the “2024 New Technologies, New Products, and New Models List in Hefei”

The Group’s product Treprostinil Injection featured in the “2024 New Technologies, New Products, and New Models List in Hefei”

Recently, the Hefei Science and Technology Bureau of Anhui Province announced the proposed list of “New Technologies, New Products, and New Models in Hefei for 2024.” After rounds of selection, the Treprostinil Injection, a product of Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke Hefei”), which is a wholly-owned subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” […]

Lee’s Pharm participated in the 12th China Cervical Cancer Prevention and Control Conference, and won “Social Responsibility Award”

Lee’s Pharm participated in the 12th China Cervical Cancer Prevention and Control Conference, and won “Social Responsibility Award”

The 12th China Cervical Cancer Prevention and Control Academic Annual Conference, hosted by the China Cervical Cancer Prevention and Control Engineering Committee, was successfully held in Chongqing from 17-20 October 2024. The conference aimed to standardize diagnosis and treatment pathways and achieve precise diagnosis and management for cervical cancer. Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke […]

Lee’s Pharm participated in BIOHK2024, focusing on rare disease drug innovation

Lee’s Pharm participated in BIOHK2024, focusing on rare disease drug innovation

The Hong Kong International Biotechnology Forum and Exhibition (BIOHK2024), organized by the Hong Kong Biotechnology Organization, was successfully held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 11-14 September 2024. It is one of Asia’s largest international biotechnology conventions which aims to facilitate the exchange of ideas among international industry players and foster […]

The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched

The Group’s in-house developed product Adapalene and Clindamycin Hydrochloride Gel was successfully launched

May 30, 2024, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) grandly held the launch ceremony at its Guangzhou Nansha site for its new product Adapalene and Clindamycin Hydrochloride Gel. The Group’s Managing Director, Ms. Wanee Leelalertsuphakun, and staff members of different departments were present at the event to jointly witness the start […]

The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

The Group’s in-licensed products INOmax® and INOmax DSIR Plus were successfully launched

Recently, the “Symposium on the Progress of Nitric Oxide Inhalation Therapy in Newborns” organized by the Shanghai Caritas Foundation took place at the Guangzhou Southern Airlines Pearl Airport Hotel. During the conference, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) held a launch event for its new rare disease products, Nitric Oxide for […]

Lee’s Pharmaceutical participated in the 88th PharmChina

Lee’s Pharmaceutical participated in the 88th PharmChina

May 15, 2024, the high-profile 88th PharmChina was grandly opened at the Shanghai National Exhibition and Convention Center. As a significant event in the industry, the exhibition attracted 150,000 visitors and brought together nearly 4,000 pharmaceutical companies to showcase their latest products and technological achievements. Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) […]

Azilsartan Tablets won the “Guangdong Prominent High-tech Products” award

Azilsartan Tablets won the “Guangdong Prominent High-tech Products” award

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Prominent High-tech Products” for 2023. The Azilsartan Tablets, an in-house developed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), won the award by virtue of its outstanding innovation capacity, advanced technology, reliable quality and good market prospect. ดาวน์โหลดข่าวฉบับเต็ม (PDF) ที่มา: Lee’s […]

Zhaoke-Hefei was honored with the “Safe Enterprise” title in Hefei for the year 2023

Zhaoke-Hefei was honored with the “Safe Enterprise” title in Hefei for the year 2023

Recently, the Hefei Municipal Department of Economy and Information Technology announced the list of “Safe Enterprises” for the year 2023. After several rounds of selection, Zhaoke Pharmaceutical (Hefei) Company Limited (“Zhaoke-Hefei”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, HKEx:00950), has been honored with this title. ดาวน์โหลดข่าวฉบับเต็ม (PDF) ที่มา: Lee’s Pharmaceutical […]

thThai